The Role of miR-330-3p/PKC-α Signaling Pathway in Low-Dose Endothelial-Monocyte Activating Polypeptide-II Increasing the Permeability of Blood-Tumor Barrier.

Jiahui Liu,Libo Liu,Shuo Chao,Yunhui Liu,Xiaobai Liu,Jian Zheng,Jiajia Chen,Wei Gong,Hao Teng,Zhen Li,Ping Wang,Yixue Xue
DOI: https://doi.org/10.3389/fncel.2017.00358
2017-01-01
Frontiers in Cellular Neuroscience
Abstract:This study was performed to determine whether EMAP II increases the permeability of the blood-tumor barrier (BTB) by affecting the expression of miR-330-3p as well as its possible mechanisms. We determined the over-expression of miR-330-3p in glioma microvascular endothelial cells (GECs) by Real-time PCR. Endothelial monocyte-activating polypeptide-II (EMAP-II) significantly decreased the expression of miR-330-3p in GECs. Pre-miR-330-3p markedly decreased the permeability of BTB and increased the expression of tight junction (TJ) related proteins ZO-1, occludin and claudin-5, however, anti-miR-330-3p had the opposite effects. Anti-miR-3303p could enhance the effect of EMAP-II on increasing the permeability of BTB, however, pre-miR-330-3p partly reversed the effect of EMAP-II on that. Similarly, anti-miR-330-3p improved the effects of EMAP-II on increasing the expression levels of PKC-alpha and p-PKC-alpha in GECs and pre-miR-330-3p partly reversed the effects. MiR-330-3p could target bind to the 3 0 UTR of PKC-alpha. The results of in vivo experiments were similar to those of in vitro experiments. These suggested that EMAP-II could increase the permeability of BTB through inhibiting miR-330-3p which target negative regulation of PKC-alpha. Pre-miR-330-3p and PKC-a inhibitor decreased the BTB permeability and up-regulated the expression levels of ZO-1, occludin and claudin-5 while anti-miR-330-3p and PKC-a activator brought the reverse effects. Compared with EMAP-II, anti-miR-330-3p and PKC-a activator alone, the combination of the three combinations significantly increased the BTB permeability. EMAP-II combined with anti-miR-330-3p and PKC-alpha activator could enhance the DOX's effects on inhibiting the cell viabilities and increasing the apoptosis of U87 glioma cells. Our studies suggest that low-dose EMAP-II up-regulates the expression of PKC-a and increases the activity of PKC-alpha by inhibiting the expression of miR-330-3p, reduces the expression of ZO-1, occludin and claudin-5, and thereby increasing the permeability of BTB. The results can provide a new strategy for the comprehensive treatment of glioma.
What problem does this paper attempt to address?